synthetic biology

Jared Friedman explains why hard tech and biotech companies face both market and technical risk, and why ambitious ideas can make recruiting, press, and fundraising easier even when building the product is difficult. He shares ways to demonstrate progress before a costly product is ready, including prototypes, simulations, small-scale experiments, presales, letters of intent, and customer contracts. He recommends proving demand and reducing technical risk as early as possible. He also advises founders to break a large fundraising goal into smaller rounds tied to concrete milestones.

Sam Altman explains that early B2B sales often come from expanding a founder’s network, building something impressive, and using founder-to-founder introductions. He weighs the advantages and disadvantages of starting a company young, and advises nontechnical founders to excel at product and leadership while finding technical partners they know and trust. He discusses why equity crowdfunding has not yet reached its promise and urges students to develop their own convictions about important fields, including AI, biotechnology, clean energy, education, and VR/AR. He also describes how new computing platforms can create clusters of major companies, suggesting that daily usage is a better signal than device shipments, and shares advice on integrating an acquired company while preserving autonomy and building relationships.